What are the initiation recommendations for OHTUVAYRE (ensifentrine) in adults with moderate-to-severe chronic obstructive pulmonary disease?

OHTUVAYRE Initiation Recommendations

OHTUVAYRE (ensifentrine) 3 mg twice daily via nebulizer should be initiated in adults with moderate-to-severe COPD who remain symptomatic despite standard maintenance therapy with long-acting bronchodilators (LABA/LAMA) or combination therapy (ICS/LABA/LAMA). 1

FDA-Approved Indication and Dosing

OHTUVAYRE is FDA-approved for maintenance treatment of COPD in adult patients 1. The recommended dosage is 3 mg (one ampule) twice daily administered by oral inhalation using a standard jet nebulizer with a mouthpiece 1. This represents the first-in-class dual PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties 2, 3.

Patient Selection Criteria

Initiate OHTUVAYRE in patients meeting these criteria:

• Disease severity: Moderate-to-severe COPD (FEV₁ <60% predicted) 4
• Age: 40-80 years old 4
• Symptomatic status: Persistent breathlessness, cough, or activity limitation despite current therapy 5, 4
• Background therapy: Already on maintenance bronchodilators (LABA, LAMA, or combinations) 4

Clinical Context Within COPD Treatment Algorithm

While established guidelines recommend stepwise escalation from bronchodilators to combination therapy 6, 7, 8, OHTUVAYRE represents a novel add-on option. Traditional guidelines suggest:

• Moderate COPD: Regular bronchodilator therapy with LABA or LAMA, consider ICS trial 6, 7
• Severe COPD: Combination LABA/LAMA or ICS/LABA/LAMA 7, 8

OHTUVAYRE fits as an adjunctive therapy when patients remain symptomatic on these standard regimens, offering a complementary mechanism of action through dual PDE3/PDE4 inhibition 3, 9.

Expected Clinical Benefits

Lung function improvements occur rapidly and are sustained:

• Peak FEV₁: Increases by 135-154 mL (evident from day 1) 4
• Average FEV₁: Improves by 90 mL at 12 weeks 5, 4
• Morning trough FEV₁: Gains of 42-44 mL 5, 4

Symptom and quality of life benefits:

• Significant improvement in E-RS:COPD respiratory symptom scores 5
• Enhanced Transition Dyspnea Index scores 5
• Reduced exacerbation rates and risk 10

Safety Considerations and Contraindications

Absolute contraindication: Hypersensitivity to ensifentrine or any component 1

Important warnings:

• Not for acute bronchospasm - this is maintenance therapy only 1
• Psychiatric effects: Increased risk of depression and suicidal ideation reported; carefully weigh risks in patients with psychiatric history 1
• Paradoxical bronchospasm: Discontinue immediately if occurs 1
• Hepatic impairment: Use with caution as drug exposure increases 1

Adverse event profile is favorable: Most common reactions (≥1%) include back pain, hypertension, urinary tract infection, and diarrhea - rates similar to placebo 1, 5, 4

Practical Initiation Steps

1. Confirm diagnosis: Moderate-to-severe COPD with FEV₁ <60% predicted and persistent symptoms
2. Verify background therapy: Patient should be on optimized maintenance bronchodilators
3. Screen for contraindications: Particularly psychiatric history and hepatic function
4. Prescribe: 3 mg twice daily via standard jet nebulizer with mouthpiece 1
5. Patient education: Emphasize this is maintenance therapy, not rescue medication
6. Monitor response: Assess lung function and symptoms at 12 weeks; benefits begin within 24 hours 4

Combination Therapy Considerations

OHTUVAYRE demonstrates synergistic effects when combined with existing COPD medications 9. It can be safely added to:

• LAMA monotherapy
• LABA/LAMA combinations
• ICS/LABA/LAMA triple therapy

The dual PDE3/PDE4 mechanism provides complementary bronchodilation and anti-inflammatory activity beyond traditional inhaler therapies 3, 9. Notably, combination with roflumilast (another PDE4 inhibitor) has been tolerated in limited case series 11, though this requires careful monitoring.

Key Clinical Pitfalls to Avoid

• Do not use for acute exacerbations - this is maintenance therapy only
• Do not delay initiation waiting for complete optimization of other therapies - benefits are additive
• Do not overlook psychiatric screening before initiation given increased risk of mood changes
• Do not prescribe without proper nebulizer equipment - requires standard jet nebulizer, not other delivery devices